ArticleEuropean heart journal2024
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.
Article in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations.European heart journal. Quality of care & clinical outcomes · 2025Pooled it
- Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2025Pooled it
- Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study.Journal of the American Heart Association · 2026Trial
- Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.Journal of cardiac failure · 2026Article
- Grapefruit-Mavacamten Interaction Leading to Reduced Ejection Fraction: When Energy Drinks Aren't So Energizing.JACC. Case reports · 2026Article
- Left Atrial Volume Index, Left Ventricular Outflow Tract Gradient, and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2026Article
- Mavacamten's Dose-Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.European heart journal · 2026Article
- Efficacy and safety of sodium-glucose cotransporter inhibitors in hypertrophic cardiomyopathy: a systematic review.International journal of cardiology. Heart & vasculature · 2026Article
- Aficamten: First Approval.Drugs · 2026Review
- Response to comment on "CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy".European journal of clinical pharmacology · 2026Article
- Myectomy with secondary chordal resection in hypertrophic obstructive cardiomyopathy: the mid-term outcomes.Journal of cardiothoracic surgery · 2026Article
- Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data.Journal of the American Heart Association · 2026Observational
- [Update on hypertrophic cardiomyopathy].Innere Medizin (Heidelberg, Germany) · 2026Review
- Long-Term Follow-Up After Discontinuation of Mavacamten in Hypertrophic Obstructive Cardiomyopathy.CJC open · 2026Article
- Biomarkers as Clinical Endpoints in Hypertrophic Cardiomyopathy Clinical Trials.Current heart failure reports · 2026Review
- Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors.ESC heart failure · 2026Article
- One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling.European heart journal. Case reports · 2026Article
- Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
BACKGROUND AND
aimsLong-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten.
methodsParticipants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion.
resultsAt the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0-228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): resting, -40.3 (32.7) mmHg; Valsalva, -55.3 (33.7) mmHg], N-terminal pro B-type natriuretic peptide [median (interquartile range): -562 (-1162.5, -209) ng/L], and EQ-5D-5L score [mean (standard deviation): 0.09 (0.17)]. Mean left ventricular ejection fraction (LVEF) decreased from 73.9% (baseline) to 66.6% (Week 24) and 63.9% (Week 180). At Week 180, 74 (77.9%) of the 95 patients improved by at least one New York Heart Association class from baseline. Over 739 patient-years exposure, 20 patients (8.7%; exposure-adjusted incidence: 2.77/100 patient-years) experienced 22 transient reductions in LVEF to <50% resulting in temporary treatment interruption (all recovered LVEF of ≥50%). Five (2.2%) patients died (all considered unrelated to mavacamten).
conclusionsLong-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.